Pain reprocessing therapy provides pain relief in chronic back pain: JAMA
USA: A recent study in JAMA Psychiatry has reported psychological treatment aimed at changing patients' beliefs about the causes and threat value of pain in patients with chronic back pain (CBP) to be associated with substantial and durable pain relief.Chronic back pain is a leading cause of disability whose treatment is often ineffective. 85% of cases are of primary CBP for which...
USA: A recent study in JAMA Psychiatry has reported psychological treatment aimed at changing patients' beliefs about the causes and threat value of pain in patients with chronic back pain (CBP) to be associated with substantial and durable pain relief.
Chronic back pain is a leading cause of disability whose treatment is often ineffective. 85% of cases are of primary CBP for which peripheral etiology cannot be identified, and maintenance factors include avoidance, fear, and beliefs that pain indicates injury. Yoni K. Ashar, Department of Psychiatry, Weill Cornell Medical College, New York City, New York, and colleagues aimed to test whether a psychological treatment (pain reprocessing therapy [PRT]) aiming to shift patients' beliefs about the causes and threat value of pain provides substantial and durable pain relief from primary CBP and to investigate treatment mechanism in a randomized clinical trial.
33 of 50 participants (66%) were randomized to 4 weeks of pain reprocessing therapy and 10 of 51 participants (20%) were randomized to placebo and 5 of 50 participants (10%) were randomized to usual care.
Main outcomes include a one-week mean back pain intensity score (0 to 10) at posttreatment, pain beliefs, and fMRI measures of evoked pain and resting connectivity.
Participants randomized to PRT participated in 1 telehealth session with a physician and 8 psychological treatment sessions over 4 weeks. Treatment aimed to help patients reconceptualize their pain as due to nondangerous brain activity rather than peripheral tissue injury, using a combination of cognitive, somatic, and exposure-based techniques. Participants randomized to placebo received an open-label subcutaneous saline injection in the back; participants randomized to usual care continued their routine, ongoing care.
Key findings include:
- Large group differences in pain were observed at posttreatment, with a mean pain score of 1.18 in the PRT group, 2.84 in the placebo group, and 3.13 in the usual care group.
- Hedges g was −1.14 for PRT vs placebo and −1.74 for PRT vs usual care.
- Of 151 total participants, 33 of 50 participants (66%) randomized to PRT were pain-free or nearly pain-free at posttreatment (reporting a pain intensity score of 0 or 1 of 10), compared with 10 of 51 participants (20%) randomized to placebo and 5 of 50 participants (10%) randomized to usual care.
- Treatment effects were maintained at 1-year follow-up, with a mean pain score of 1.51 in the PRT group, 2.79 in the placebo group, and 3.00 in the usual care group. Hedges g was −0.70 for PRT vs placebo and −1.05 for PRT vs usual care at 1-year follow-up.
- Longitudinal fMRI showed (1) reduced responses to evoked back pain in the anterior midcingulate and the anterior prefrontal cortex for PRT vs placebo; (2) reduced responses in the anterior insula for PRT vs usual care; (3) increased resting connectivity from the anterior prefrontal cortex and the anterior insula to the primary somatosensory cortex for PRT vs both control groups; and (4) increased connectivity from the anterior midcingulate to the precuneus for PRT vs usual care.
"Overall, our findings raise key possibilities about the nature and treatment of primary CBP. Changing fear- and avoidance-inducing beliefs about the causes and threat value of pain may provide substantial, durable pain relief for people with primary CBP," concluded the authors.
Reference:
Ashar YK, Gordon A, Schubiner H, et al. Effect of Pain Reprocessing Therapy vs Placebo and Usual Care for Patients With Chronic Back Pain: A Randomized Clinical Trial. JAMA Psychiatry. Published online September 29, 2021. doi:10.1001/jamapsychiatry.2021.2669
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd